Expanded Access to ABBV-706
- Sponsor
- AbbVie
- Study ID
- NCT07310277
- Status
- Available
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ABBV-706 — DRUGIntravenous (IV) Infusion
Study Details
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-706 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Key Dates
- Status verified
- Dec 2025
Central Contacts
- ABBVIE CALL CENTER844-663-3742
Related Studies
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56PHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)Recruiting · Tempus AI · Los Alamitos, California